| Literature DB >> 30831192 |
Juan Arranz1, Elisa Balducci1, Krisztina Arató2, Gentzane Sánchez-Elexpuru3, Sònia Najas4, Alberto Parras5, Elena Rebollo4, Isabel Pijuan1, Ionas Erb6, Gaetano Verde6, Ignasi Sahun7, Maria J Barallobre1, José J Lucas8, Marina P Sánchez3, Susana de la Luna9, Maria L Arbonés10.
Abstract
Autism spectrum disorders are early onset neurodevelopmental disorders characterized by deficits in social communication and restricted repetitive behaviors, yet they are quite heterogeneous in terms of their genetic basis and phenotypic manifestations. Recently, de novo pathogenic mutations in DYRK1A, a chromosome 21 gene associated to neuropathological traits of Down syndrome, have been identified in patients presenting a recognizable syndrome included in the autism spectrum. These mutations produce DYRK1A kinases with partial or complete absence of the catalytic domain, or they represent missense mutations located within this domain. Here, we undertook an extensive biochemical characterization of the DYRK1A missense mutations reported to date and show that most of them, but not all, result in enzymatically dead DYRK1A proteins. We also show that haploinsufficient Dyrk1a+/- mutant mice mirror the neurological traits associated with the human pathology, such as defective social interactions, stereotypic behaviors and epileptic activity. These mutant mice present altered proportions of excitatory and inhibitory neocortical neurons and synapses. Moreover, we provide evidence that alterations in the production of cortical excitatory neurons are contributing to these defects. Indeed, by the end of the neurogenic period, the expression of developmental regulated genes involved in neuron differentiation and/or activity is altered. Therefore, our data indicate that altered neocortical neurogenesis could critically affect the formation of cortical circuits, thereby contributing to the neuropathological changes in DYRK1A haploinsufficiency syndrome.Entities:
Keywords: Autism spectrum disorder; Cerebral cortex; DYRK1A mutations; Epilepsy; Neurodevelopment; Transcriptome
Mesh:
Substances:
Year: 2019 PMID: 30831192 PMCID: PMC6753933 DOI: 10.1016/j.nbd.2019.02.022
Source DB: PubMed Journal: Neurobiol Dis ISSN: 0969-9961 Impact factor: 5.996